{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:08:57Z","timestamp":1763003337673,"version":"3.45.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA248493","R01 CA252937"],"award-info":[{"award-number":["R01 CA248493","R01 CA252937"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10HL069294","U24HL138660"],"award-info":[{"award-number":["U10HL069294","U24HL138660"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jtct.2022.05.019","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T01:49:24Z","timestamp":1653097764000},"page":"446-454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9342-5635","authenticated-orcid":false,"given":"Sarah A.","family":"Holstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fotis","family":"Asimakopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6371-2780","authenticated-orcid":false,"given":"Abdel Kareem","family":"Azab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giada","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manisha","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0704-0067","authenticated-orcid":false,"given":"Leslie A.","family":"Crews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1095-4273","authenticated-orcid":false,"given":"Tom","family":"Cupedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6292-3802","authenticated-orcid":false,"given":"Hannah","family":"Giles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Gooding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8178-6890","authenticated-orcid":false,"given":"Lukas","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shari","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-4854","authenticated-orcid":false,"given":"Kylee","family":"Maclachlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo C.","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Pichiorri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Shokeen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian R.","family":"Shy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raluca","family":"Verona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip L.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.05.019_bib0001","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2017.12.774","article-title":"BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: summary and recommendations from the organizing committee","volume":"24","author":"Holstein","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.05.019_bib0002","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.bbmt.2018.11.001","article-title":"Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling","volume":"25","author":"Holstein","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.05.019_bib0003","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.bbmt.2019.09.015","article-title":"Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling","volume":"26","author":"Holstein","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.05.019_bib0004","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.bbmt.2020.06.011","article-title":"Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling","volume":"26","author":"Holstein","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.05.019_bib0005","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jtct.2021.05.027","article-title":"The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma","volume":"27","author":"Holstein","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.05.019_bib0006","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1182\/blood-2011-07-368050","article-title":"P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment","volume":"119","author":"Azab","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.05.019_bib0007","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1158\/1078-0432.CCR-13-0462","article-title":"Cell trafficking of endothelial progenitor cells in tumor progression","volume":"19","author":"de la Puente","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2022.05.019_bib0008","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1182\/blood-2014-02-558742","article-title":"CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma","volume":"124","author":"Azab","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.05.019_bib0009","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/417586","article-title":"Inhibition of P-selectin and PSGL-1 using humanized monoclonal antibodies increases the sensitivity of multiple myeloma cells to bortezomib","volume":"2015","author":"Muz","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jtct.2022.05.019_bib0010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-019-0227-3","article-title":"Inhibition of E-selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy","volume":"9","author":"Muz","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2022.05.019_bib0011","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1038\/s41467-020-19932-1","article-title":"Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma","volume":"11","author":"Federico","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2022.05.019_bib0012","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee report","volume":"11","author":"Murray","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2022.05.019_bib0013","series-title":"Abstract presented at the 73rd AACC Annual Scientific Meeting. 26-30","article-title":"Multi-site verification of the automated EXTENT\u00ae MALDI-TOF-MS system and immunoglobulin isotypes assay for the identification and quantification of monoclonal immunoglobulins","author":"Marrot","year":"2021"},{"key":"10.1016\/j.jtct.2022.05.019_bib0014","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood.2021013794","article-title":"Redefining nonmeasurable multiple myeloma using mass spectrometry","volume":"139","author":"Giles","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.05.019_bib0015","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood-2017-09-807263","article-title":"Copper 64-labeled daratumumab as a PET\/CT imaging tracer for multiple myeloma","volume":"131","author":"Caserta","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.05.019_bib0016","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1182\/bloodadvances.2020002603","article-title":"Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumab","volume":"4","author":"Krishnan","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.05.019_bib0017","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.120.251983","article-title":"Comparison of CD38-targeted \u03b1- versus \u03b2-radionuclide therapy of disseminated multiple myeloma in an animal model","volume":"62","author":"Minnix","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jtct.2022.05.019_bib0018","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.05.019_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2967\/jnumed.115.163808","article-title":"New approaches to molecular imaging of multiple myeloma","volume":"57","author":"Vij","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jtct.2022.05.019_bib0020","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2967\/jnumed.117.196063","article-title":"Preclinical development of CD38-targeted [89Zr]Zr-DFO-daratumumab for imaging multiple myeloma","volume":"59","author":"Ghai","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jtct.2022.05.019_bib0021","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1148\/radiol.2020192621","article-title":"CD38-targeted immuno-PET of multiple myeloma: from xenograft models to first-in-human imaging","volume":"295","author":"Ulaner","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.jtct.2022.05.019_bib0022","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1007\/s00259-020-05097-y","article-title":"Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma","volume":"48","author":"Ghai","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jtct.2022.05.019_bib0023","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13550-021-00840-4","article-title":"In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [18F]FDG and [64Cu]Cu-LLP2A PET","volume":"11","author":"Ghai","year":"2021","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.jtct.2022.05.019_bib0024","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41598-021-03748-0","article-title":"Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival","volume":"12","author":"Hathi","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtct.2022.05.019_bib0025","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.2020006540","article-title":"Cancer immunoediting and immune dysregulation in multiple myeloma","volume":"136","author":"Nakamura","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.05.019_bib0026","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1369\/0022155420937098","article-title":"Versican and versican-matrikines in cancer progression, inflammation, and immunity","volume":"68","author":"Papadas","year":"2020","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.jtct.2022.05.019_bib0027","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1182\/blood-2014-02-554071","article-title":"TPL2 kinase regulates the inflammatory milieu of the myeloma niche","volume":"123","author":"Hope","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.05.019_bib0028","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.celrep.2015.11.053","article-title":"Toll-like receptor 2 activation promotes tumor dendritic cell dysfunction by regulating IL-6 and IL-10 receptor signaling","volume":"13","author":"Tang","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.jtct.2022.05.019_bib0029","article-title":"Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy","volume":"5","author":"Bailur","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtct.2022.05.019_bib0030","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1158\/2159-8290.CD-17-0284","article-title":"Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers","volume":"8","author":"Pearce","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtct.2022.05.019_bib0031","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","article-title":"A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells","volume":"184","author":"Cheng","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jtct.2022.05.019_bib0032","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40425-018-0376-0","article-title":"Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers","volume":"6","author":"Mushtaq","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2022.05.019_bib0033","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.4049\/jimmunol.1700529","article-title":"Versican-derived matrikines regulate Batf3-dendritic cell differentiation and promote T cell infiltration in colorectal cancer","volume":"199","author":"Hope","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.jtct.2022.05.019_bib0034","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1080\/10428194.2019.1585836","article-title":"Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma","volume":"60","author":"Dhakal","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.05.019_bib0035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41588-019-0576-7","article-title":"Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing","volume":"52","author":"Cort\u00e9s-Ciriano","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtct.2022.05.019_bib0036","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/2643-3230.BCD-20-0132","article-title":"Revealing the impact of structural variants in multiple myeloma","volume":"1","author":"Rustad","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.jtct.2022.05.019_bib0037","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.semcdb.2021.04.014","article-title":"Chromothripsis as a pathogenic driver of multiple myeloma","volume":"123","author":"Maura","year":"2022","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.jtct.2022.05.019_bib0038","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1038\/s41467-021-25469-8","article-title":"Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma","volume":"12","author":"Maclachlan","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2022.05.019_bib0039","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/s41467-021-22140-0","article-title":"Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities","volume":"12","author":"Oben","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2022.05.019_bib0040","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","article-title":"The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape","volume":"22","author":"de Jong","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jtct.2022.05.019_bib0041","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2022.05.019_bib0042","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood-2018-04-842880","article-title":"The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma","volume":"132","author":"Rasche","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.05.019_bib0043","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.05.019_bib0044","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.05.019_bib0045","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood.2020007081","article-title":"Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma","volume":"137","author":"Gooding","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.05.019_bib0046","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jtct.2022.05.019_bib0047","article-title":"Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jtct.2022.05.019_bib0048","doi-asserted-by":"crossref","first-page":"85392","DOI":"10.18632\/oncotarget.19907","article-title":"Bone marrow IRF4 level in multiple myeloma: an indicator of peripheral blood Th17 and disease","volume":"8","author":"Bai","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtct.2022.05.019_bib0049","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2011.08689.x","article-title":"Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response","volume":"154","author":"Lopez-Girona","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.05.019_bib0050","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.leukres.2018.07.025","article-title":"IRF4 in multiple myeloma-biology, disease and therapeutic target","volume":"72","author":"Agnarelli","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.jtct.2022.05.019_bib0051","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.stem.2020.12.017","article-title":"Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption","volume":"28","author":"Mondala","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jtct.2022.05.019_bib0052","article-title":"Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells","volume":"2","author":"Vora","year":"2021","journal-title":"STAR Protoc"},{"key":"10.1016\/j.jtct.2022.05.019_bib0053","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/s41467-017-01890-w","article-title":"Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma","volume":"8","author":"Lazzari","year":"2017","journal-title":"Nat Commun"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.05.019_bib0054","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood-2021-146868","article-title":"Updated phase 1 results from MonumenTAL-1: first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma","volume":"138","author":"Krishnan","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.05.019_bib0055","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2021-147915","article-title":"Updated results from MajesTEC-1: phase 1\/2 study of teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in relapsed\/refractory multiple myeloma","volume":"138","author":"Moreau","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.05.019_bib0056","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2022.05.019_bib0057","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.05.019_bib0058","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","article-title":"Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM","volume":"5","author":"Truger","year":"2021","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.05.019_bib0059","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood-2021-152149","article-title":"Mapping the multiple myeloma T cell landscape by immunotherapeutic perturbation reveals mechanism and determinants of response to bispecific T cell engagers","volume":"138","author":"Friedrich","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.05.019_bib0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-137650","article-title":"Cite-Seq profiling of T cells in multiple myeloma patients undergoing BCMA targeting CAR-T or BITEs immunotherapy","volume":"136","author":"Leblay","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.05.019_bib0061","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.jtct.2022.05.019_bib0062","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2326-6066.CIR-20-0080","article-title":"A CRISPR screen reveals resistance mechanisms to CD3-bispecific antibody therapy","volume":"9","author":"Liu","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtct.2022.05.019_bib0063","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fonc.2020.00636","article-title":"Deregulation of adaptive T cell immunity in multiple myeloma: insights into mechanisms and therapeutic opportunities","volume":"10","author":"Leblay","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2022.05.019_bib0064","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1097\/HS9.0000000000000575","article-title":"Understanding the mechanisms of resistance to T cell-based immunotherapies to develop more favorable strategies in multiple myeloma","volume":"5","author":"Ahn","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.jtct.2022.05.019_bib0065","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/s41375-020-01089-x","article-title":"Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia","volume":"35","author":"Wei","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.05.019_bib0066","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/s41467-021-21445-4","article-title":"Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation","volume":"12","author":"Arenas","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2022.05.019_bib0067","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2013.231","article-title":"Histone deacetylase 3 as a novel therapeutic target in multiple myeloma","volume":"28","author":"Minami","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.05.019_bib0068","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41375-019-0493-x","article-title":"Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling","volume":"34","author":"Ho","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.05.019_bib0069","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.05.019_bib0070","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1182\/blood-2021-146060","article-title":"Updated results from CARTITUDE-1: phase 1b\/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed\/refractory multiple myeloma","volume":"138","author":"Martin","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.05.019_bib0071","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2020-134378","article-title":"Idecabtagene vicleucel (ide-cel, bb2121) responses are characterized by early and temporally consistent activation and expansion of CAR T cells with a T effector phenotype","volume":"136","author":"Martin","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.05.019_bib0072","series-title":"Paper presented at: 25th Congress of the European Hematology Association (EHA25 Virtual). 11-21","article-title":"Correlation of tumor BCMA expression with response and acquired resistance to idecabtagene vicleucel in the KarMMa study in relapsed and refractory multiple myeloma","author":"Martin","year":"2020"},{"key":"10.1016\/j.jtct.2022.05.019_bib0073","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41587-019-0325-6","article-title":"Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency","volume":"38","author":"Nguyen","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtct.2022.05.019_bib0074","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","article-title":"Reprogramming human T cell function and specificity with non-viral genome targeting","volume":"559","author":"Roth","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jtct.2022.05.019_bib0075","doi-asserted-by":"crossref","first-page":"10437","DOI":"10.1073\/pnas.1512503112","article-title":"Generation of knock-in primary human T cells using Cas9 ribonucleoproteins","volume":"112","author":"Schumann","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtct.2022.05.019_bib0076","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jtct.2022.05.019_bib0077","article-title":"AAV manufacturing for clinical use: insights on current challenges from the upstream process perspective","volume":"20","author":"Dobrowsky","year":"2021","journal-title":"Curr Opin Biomed Eng"},{"key":"10.1016\/j.jtct.2022.05.019_bib0078","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2022.05.019_bib0079","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.05.019_bib0080","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2022.05.019_bib0081","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11:eaau7746","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.05.019_bib0082","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2021-153204","article-title":"Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma","volume":"138","author":"Mailankody","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.05.019_bib0083","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/2643-3230.BCD-20-0122","article-title":"Dual targeting with CAR T cells to limit antigen escape in multiple myeloma","volume":"1","author":"Simon","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.jtct.2022.05.019_bib0084","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting bcma and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma","volume":"1","author":"Fern\u00e1ndez de Larrea","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.jtct.2022.05.019_bib0085","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722013124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722013124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:04:29Z","timestamp":1763003069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722013124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":85,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2666636722013124"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.05.019","relation":{},"ISSN":["2666-6367"],"issn-type":[{"type":"print","value":"2666-6367"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}